Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

Bone Marrow Transplantation

Volumn 43, Issue 5, 2009, Pages 417-422

  Olin, R L ^a   Vogl, D T ^a   Porter, D L ^a   Luger, S M ^a   Schuster, S J ^a   Tsai, D E ^a   Siegel, D L ^a   Cook, R J ^a   Mangan, P A ^a   Cunningham, K ^a   Stadtmauer, E A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 62549086569     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.334     Document Type: Article

References (18)

1. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
4. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253.
5. Mehta J. One or two autografts for myeloma? Blood 2008; 111: 3899-3900.
6. Reece DE. Management of multiple myeloma: The changing landscape. Blood Rev 2007; 21: 301-314.
7. Mikhael JR, Zadeh S, Samiee S. Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relased multiple myeloma: Improved outcomes in patients with longer disease free interval after first ASCT. Blood 2007; 110: (abstract 946).
8. Simpson L, Verma R, Kumar S. Outcome after second stem cell transplantation for relapsed multiple myeloma. J Clin Oncol 2007; 25: (abstract 8118).
9. Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 1101-1114.
10. Abdelke. A, Ladeb S, Ben Othman T. Timing of second autologous transplantations in multiple myeloma: Results of a multicenter sequential randomized clinical trial. Blood 2006; 108: (abstract 59).
11. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006; 106: 1084-1089.
12. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006; 91: 141-142.
13. Lee CK, Barlogie B, Fassas A. Third autotransplant for the management of 98 patients among 1358 who had received prior tandem autotransplants: Benefit apparent when 2nd to 3rd transplant interval exceeds 3 years. Blood 2004; 104: (abstract 540).
14. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D et al Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887-892.
15. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy. Bone Marrow Transplant 1995; 16: 7-11.
16. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
17. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008; 42: 413-420.
18. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial. Blood 2008; 111: 1805-1810.